Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5158192 | 0.90 | PTGS2 (0.36) | MEN1KMT2APTGS2TDP1SLC6A2 | |
| SCHEMBL5160157 | 0.86 | SLC6A3 (0.38) | MEN1KMT2APTGS1PTGS2TDP1 | |
| SCHEMBL5159946 | 0.80 | KIF11 (0.40) | PTGS1PTGS2SLC6A4TSHR | |
| SCHEMBL5158439 | 0.78 | CHRNB4 (0.41) | MEN1KMT2ASLC6A2SLC6A4TSHR | |
| SCHEMBL5161115 | 0.78 | TDP1 (0.40) | MEN1KMT2ATDP1SLC6A2SLC6A4 | |
| SCHEMBL5160367 | 0.75 | CHRNA7 (0.33) | MEN1KMT2ATSHRMAPK1 | |
| SCHEMBL5160356 | 0.70 | MEN1 (0.34) | MEN1KMT2ATDP1SLC6A2SLC6A4 | |
| SCHEMBL5160234 | 0.69 | MEN1 (0.43) | MEN1KMT2ASLC6A2SLC6A4 | |
| SCHEMBL5159622 | 0.69 | MEN1 (0.36) | MEN1KMT2ATDP1 | |
| SCHEMBL8389316 | 0.69 | MAPK14 (0.64) | MAPK14PTGS1PTGS2SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1406857-B1 | SUBSTITUTED 1-ARYL-BUT-3-ENYLAMINE AND 1-ARYL-BUT-2-ENYLAMINE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2007-02-21 | — | — | EP | claimed |
| US-7064236-B2 | Substituted 1-aryl-but-3-enylamine and 1-aryl-but-2-enylamine compounds | GRUNENTHAL GMBH (DE) | 2006-06-20 | — | — | US | claimed |
| US-20040171615-A1 | Substituted 1-aryl-but-3-enylamine and 1-aryl-but-2-enylamine compounds | GRUNENTHAL GMBH (DE) | 2004-09-02 | — | — | US | claimed |
| EP-1406857-A1 | SUBSTITUTED 1-ARYL-BUT-3-ENYLAMINE AND 1-ARY-BUT-2-ENYLAMINE COMPOUNDS | Grünenthal GmbH (DE) | 2004-04-14 | — | — | EP | claimed |
| WO-2003004452-A1 | SUBSTITUTED 1-ARYL-BUT-3-ENYLAMINE AND 1-ARY-BUT-2-ENYLAMINE COMPOUNDS | Grünenthal GmbH (DE) | 2003-01-16 | — | — | WO | claimed |
| EP-1406857-B1 | SUBSTITUTED 1-ARYL-BUT-3-ENYLAMINE AND 1-ARYL-BUT-2-ENYLAMINE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2007-02-21 | — | — | EP | disclosed |
| US-7064236-B2 | Substituted 1-aryl-but-3-enylamine and 1-aryl-but-2-enylamine compounds | GRUNENTHAL GMBH (DE) | 2006-06-20 | — | — | US | disclosed |
| US-20040171615-A1 | Substituted 1-aryl-but-3-enylamine and 1-aryl-but-2-enylamine compounds | GRUNENTHAL GMBH (DE) | 2004-09-02 | — | — | US | disclosed |
| EP-1406857-A1 | SUBSTITUTED 1-ARYL-BUT-3-ENYLAMINE AND 1-ARY-BUT-2-ENYLAMINE COMPOUNDS | Grünenthal GmbH (DE) | 2004-04-14 | — | — | EP | disclosed |
| WO-2003004452-A1 | SUBSTITUTED 1-ARYL-BUT-3-ENYLAMINE AND 1-ARY-BUT-2-ENYLAMINE COMPOUNDS | Grünenthal GmbH (DE) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171615-A1 | Substituted 1-aryl-but-3-enylamine and 1-aryl-but-2-enylamine compounds | ADRB3, BRD4, NAT1 | MEN1 1165/4885KMT2A 2909/4885MAPK14 1640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.